DBV Technologies | DBVT - Ebitda

Stock Price
22.39
Daily Change
0.80 3.71%
Monthly
31.78%
Yearly
394.26%
Q1 Forecast
21.05

DBV Technologies reported $-33.48M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amarin USD 12.54M 28.57M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Halozyme Therapeutics USD 248.25M 22.74M Sep/2025
Incyte USD 581.52M 358.87M Jun/2025
Insmed USD -297.13M 71.11M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
United Therapeutics USD 436.8M 34.2M Jun/2025